This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

5 Hated Stocks Set to Soar on Earnings

Stocks in this article: TTWOMRGEOMPIBMRNINCY

Obagi Medical Products

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

One possible earnings short-squeeze trade in the biotechnology and drugs complex is Obagi Medical Products (OMPI), which is set to release numbers on Thursday after the market close. This company develops, markets and sells, and is a provider of, topical aesthetic and therapeutic prescription-strength skin care systems and related products in the physician-dispensed market. Wall Street analysts, on average, expect Obagi Medical Products to report revenue of $30.39 million on earnings of 14 cents per share.

The current short interest as a percentage of the float for Obagi Medical Products is notable at 10.4%. That means that out of the 17.66 million shares in the tradable float, 1.89 million shares are sold short by the bears. The short-sellers have also been increasing their bets from the last reporting period by 111%, or by about 993,000 shares. That is a huge increase on a stock with an extremely low float. If Obagi Medical Products can deliver a strong quarter, then this stock will have an excellent chance of seeing a giant short-squeeze.

From a technical perspective, OMPI is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending very strong for the past six months, with shares soaring from a low of $11.07 to a recent high of $18 a share. During that monster run higher, shares of OMPI have been consistently making higher lows and higher highs, which is bullish technical price action. That said, the stock recently pulled back off that $18 high to right near its 50-day moving average of $14.55 a share.

>>5 Biotech Stocks Poised for Breakouts

If you're bullish on OMPI, then I would wait until after they report earnings and look for long-biased trades if this stock can manage to hold its trend above its 50-day moving average of $14.55 a share with strong upside volume flows. I would consider any upside volume day that registers near or above its three-month average action of 379,127 shares as bullish. If that trend for OMPI holds post-earnings, then this stock has a great chance of re-testing and possibly taking out its 52-week high of $18 a share.

I would avoid OMPI or look for short-biased trades if it fails to hold that trend after it reports, and it then takes out its 50-day at $14.55 with heavy volume. If we see that action, then OMPI could easily trade down toward $13.50 to $12 a share if the bears whack this lower post-earnings.

4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs